Vaccinex stock soars 223% on partnership deals using its antibody discovery platform (VCNX)


Summary List Placement

Vaccinex stock rocketed up more than 200% Friday, propelled by two collaboration deals centered on using the biotech company’s antibody discovery platform. 

Vaccinex, which focuses on cancer and neurodegenerative disease, said it signed multi-project deals with two unnamed “prominent” pharmaceutical companies. Financial terms of the deals were undisclosed. 

Shares jumped as much as 233% to an intraday high of $9.56 before the gains were pared to 150%. Trading volume of more than 196 million shares in late-morning action trumped the average volume of about 540,000 shares. The stock began this year at a little more than $2 each. 

The collaborations will use the company’s ActivMAb technology which Vaccinex said has multiple applications that include discovering antibodies specific for complex membrane antigens. 

Shares of Vaccinex traded at $6.18 at 12:19PM E.T. on Friday. 

Join the conversation about this story »

NOW WATCH: July 15 is Tax Day — here’s what it’s like to do your own taxes for the very first time

…read more

Source:: Business Insider


(Visited 13 times, 1 visits today)

Leave a Reply

Your email address will not be published. Required fields are marked *